Homepage
Author:
Arcutis Biotherapeutics, Inc.
Posted Date:
March 18, 2026
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
Arcutis Biotherapeutics, Inc.
March 18, 2026
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
Arcutis Biotherapeutics, Inc.
March 10, 2026
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Arcutis Biotherapeutics, Inc.
March 5, 2026
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Arcutis Biotherapeutics, Inc.
March 3, 2026
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Arcutis Biotherapeutics, Inc.
February 27, 2026
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Arcutis Biotherapeutics, Inc.
February 25, 2026
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
Arcutis Biotherapeutics, Inc.
February 24, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc.
February 8, 2026
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
Arcutis Biotherapeutics, Inc.
February 2, 2026
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
Arcutis Biotherapeutics, Inc.
January 28, 2026
Prev
1
2
3
Next
